Previous close | 0.6800 |
Open | 0.7000 |
Bid | 0.6800 |
Ask | 0.8500 |
Strike | 80.00 |
Expiry date | 2023-06-16 |
Day's range | 0.7000 - 0.7000 |
Contract range | N/A |
Volume | |
Open interest | 146 |
Incyte's (INCY) skin cancer drug approval and Altimmune's obesity data are the key highlights from the biotech sector during the past week.
Gilead Sciences (GILD) closed at $77.81 in the latest trading session, marking a -1.68% move from the prior day.
Gileads Yescarta shows statistically significant improvement in overall survival for initial treatment of R/R LBCL patients versus historical standard of care in curative setting.